Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 903 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic Radiation Therapy Clear all

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cerebral Metastases Patients
Interventions: neuropsychological testing and quality of life assessments, Standard of Care WBRT or SRS, Functional magnetic resonance imaging; Behavioral · Radiation · Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG); Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Stanford, California • Baltimore, Maryland • New York, New York

Conditions: Brain Tumor, Brain Metastases, Brain Cancer
Interventions: Reduced Dose SRS; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Indianapolis, Indiana • Portland, Oregon

Conditions: Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions: Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab; Procedure · Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colorectal Cancer, Liver Metastases
Interventions: MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Standard fractionation, Stereotactic Body Radiation Therapy (SBRT), Four Dimensional Computed Tomographic Imaging (4DCT); Other · Radiation · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Johnson Creek, Wisconsin • Madison, Wisconsin

Conditions: Emphysema
Interventions: Stereotactic Ablative Radiotherapy (SABR); Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate
Interventions: CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk; Radiation
Lead sponsor: Accuray Incorporated; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 18
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 15 more

Conditions: Brain Neoplasms, Brain Cancer
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: External Beam Radiation Therapy, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Interventions: MRI-guided SBRT, EORTC QLQ-C30 Questionnaire, EORTC QLQ-OV28 Questionnaire; Device · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Cancer
Interventions: ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT; Biological · Drug · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Locally Advanced Cervical Cancer
Interventions: SABR Boost Therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: stereotactic body radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis; Radiation · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metastatic Melanoma, Brain Metastases
Interventions: Ipilimumab, Stereotactic Radiosurgery; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer, Liver Metastases, Liver Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatic Atrophy
Interventions: Ferumoxytol injection; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions: Nivolumab, (8gy x 3), Platinum Doublet; Drug · Radiation
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more

Conditions: Prostate Cancer
Interventions: hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy; Drug · Radiation · Procedure + 1 more
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: High Grade Gliomas
Interventions: CyberKnife; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Brain Cancer
Interventions: Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastases
Interventions: Fractionated Stereotactic Radiation Therapy (FSRT); Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Lung Cancer, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Interventions: Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT); Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Neurococognitive and Functioal Assessment of Patients With Brain Metastases

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

Improving Pulmonary Function Following Radiation Therapy

Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Optimal Planning Target Volume With Stereotactic Radiosurgery

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

Short Course of Radiation for Gliomas in Elderly Patients

Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases

Phase I Study of Fractionated Stereotactic Radiation Therapy

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy